Janssen returns Phase I NASH candidate to Arrowhead
Janssen returns Phase I NASH candidate to Arrowhead
Source; BioSpace
Janssen returns Phase I NASH candidate to Arrowhead
Published: Feb 15, 2023
By Heather McKenzie
BioSpace
J&J’s Janssen Pharmaceutical has given up on an RNAi therapeutic being developed for one of biotech’s hottest targets: non-alcoholic steatohepatitis (NASH).
Janssen’s development partner, Arrowhead Pharmaceuticals, announced Wednesday it had regained full rights to the candidate, ARO-PNPLA3 (formerly JNJ-75220795).
The therapeutic stemmed from a $3.7 billion collaboration struck between the two companies in 2018. The collaboration was helmed by hepatitis B virus asset ARO-HBV and included the potential for Janssen to select up to three new targets. ARO-PNPLA3 was one of these targets.
Its Arrowhead given moniker reflects its purpose. Developed on the company’s proprietary TRiM platform, ARO-PNPLA3 is designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3), an enzyme encoded by the PNPLA3 gene.
PNPLA3 has “strong genetic and preclinical validation as a driver of fat accumulation and damage” in the livers of people carrying the I148M mutation, according to Arrowhead.
In a Phase I trial, Arrowhead reported the therapeutic elicited up to 40% mean reduction in liver fat in PNPLA3 I148M homozygotes after a single dose. ARO-PNPLA3 had a solid safety profile, with “mostly mild” adverse events and no patients discontinuing the study due to AEs.
Rohit Loomba, M.D., MHSc, professor of medicine and director of the NAFLD Research Center at University of California at San Diego, called the data “extremely encouraging” and said he looks forward to seeing the molecule progress to a later-stage study.
In Wednesday’s press release, Christopher Anzalone, Ph.D., president and CEO, Arrowhead, alluded to Janssen’s recently disclosed portfolio overhaul, saying, “We understand that Janssen is undergoing a strategic R&D portfolio review and subsequently advised us” of the decision to return full rights to ARO-PNPLA3.
Janssen’s Strategic Portfolio Review
In an early February town hall meeting, Janssen told employees it was consolidating its vaccines and infectious diseases units and undergoing a “comprehensive review” of its portfolio. This news was first reported by Fierce Pharma.
And on Tuesday, parent company J&J revealed that John Reed would take the helm as executive vice president, pharmaceuticals, R&D. On April 3, Reed will take the reins from William Hait who has served in the role since Mathai Mammen relinquished it in August 2022.
Source; BioSpace
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: